Clinical Scorecard: Comparing Immunohistochemical and Molecular Breast Cancer Subtyping in African Populations
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Comparing Immunohistochemical and Molecular Breast Cancer Subtyping in African Populations
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Population described in the source article.
Care Setting
Pathology and breast cancer care settings in Kenya and Ghana; the article notes that PAM50 profiling is seldom undertaken in routine clinical practice across African settings.
Key Highlights
The cross-sectional analysis assessed agreement between IHC-based subtype definitions and PAM50 in 460 Kenyan patients.
Findings were evaluated in a Ghanaian cohort of 451 women with invasive breast cancer.
PAM50 molecular subtypes served as the reference standard for agreement analyses.
Agreement was assessed using sensitivity, specificity, and Cohen κ statistics.
The supplied article excerpt describes the study methods but does not provide its results.
Guideline-Based Recommendations
Diagnosis
The article reports that international consensus guidance, including St Gallen recommendations, supports ER, PR, ERBB2, and Ki-67 IHC markers together with histologic grade as surrogate measures for intrinsic subtype classification.
In this study, PAM50 gene-expression profiling was used as the molecular reference standard.
Management
The article states that systemic treatment is informed by accurate subtype classification.
Monitoring & Follow-up
Not reported in the supplied excerpt.
Risks
The article describes diagnostic delays, restricted access to timely optimal treatment, and insufficient health care infrastructure as contributors to elevated breast cancer mortality in sub-Saharan Africa.
The article states that PAM50 implementation is constrained by technical complexity and substantial cost.
Patient & Prescribing Data
The study included 460 patients with invasive breast cancer in Kenya and 451 women with invasive breast cancer in Ghana; the excerpt provides no treatment or prescribing outcomes.
Subtype classification informs systemic treatment, but the excerpt reports no specific treatment regimens or prescribing recommendations.
Clinical Best Practices
The article reports that international consensus guidance supports ER, PR, ERBB2, and Ki-67 IHC results together with histologic grade as surrogate measures for intrinsic subtype classification.
The study evaluated agreement between IHC-based subtype definitions and PAM50 using sensitivity, specificity, and Cohen κ statistics.
by Shahin Sayed, Li Feng, Hela Koka, Manel Haj Mansour, Difei Wang, Maria Brown, Kristine Jones, Margaret Maina, Veronica Ngundo, Alfred Mburu Githuka, Zaitun Ajuoga, Shaoqi Fan, Amber N. Hurson, Xing Hua, Petra Lenz, Rosemary Wangari Kamau, Beryl Akinyi Ooro, Francis Makokha, Stefan Ambs, Aaron M. Rozeboom, Amy Hutchinson, Belynda Hicks, Mustapha Abubakar, Xiaohong R. Yang
The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.
